|1.||Gastroesophageal Reflux (GERD)
|1.||Fass, Ronnie: 11 articles (07/2015 - 05/2005)|
|2.||Fass, R: 10 articles (05/2014 - 12/2000)|
|3.||Miner, P B: 10 articles (04/2010 - 01/2000)|
|4.||Robinson, M: 10 articles (11/2003 - 01/2000)|
|5.||Savarino, Edoardo: 9 articles (01/2016 - 11/2006)|
|6.||Savarino, Vincenzo: 9 articles (01/2016 - 11/2006)|
|7.||Watson, David I: 9 articles (09/2015 - 11/2004)|
|8.||Devitt, Peter G: 9 articles (09/2015 - 11/2004)|
|9.||Jamieson, Glyn G: 9 articles (09/2015 - 11/2004)|
|10.||Johnson, David A: 9 articles (02/2015 - 03/2002)|
|1.||Omeprazole (Esomeprazole)FDA LinkGeneric
06/26/2000 - "Patients were assessed at weeks 2 and 4. The efficacy of omeprazole for the treatment of heartburn was determined mainly through the following diary card data: daily resolution of heartburn and complete resolution of heartburn every day during 1 week of treatment. "
01/01/1993 - "In two studies against omeprazole, no significant difference was found in healing rates, while a Scandinavian study demonstrated more prompt relief from heartburn. "
07/01/2014 - "Within the first 4 days, the proportion of subjects with heartburn-free days was significantly greater with esomeprazole 20 mg versus placebo. "
01/01/2012 - "The mean number of heartburn-free days by D7 was significantly greater in the omeprazole group: 3.7 ± 2.3 days vs. 3.1 ± 2.1 (p = 0.02). "
02/01/1993 - "Omeprazole also provided significantly greater relief from daytime heartburn, nighttime heartburn, and acid regurgitation, and was associated with decreased concomitant antacid use. "
|2.||Ranitidine (Zantac)FDA LinkGeneric
04/01/1999 - "To compare the efficacy of dosing ranitidine 75 mg or placebo 30 min prior to a proven heartburn-provoking meal in completely preventing or reducing subsequent heartburn symptoms. "
06/01/1987 - "However, the 89 evaluable ranitidine-treated patients with normal endoscopy also experienced a marked and rapid reduction in heartburn at the end of 1 wk. The symptomatic improvement in the endoscopically abnormal ranitidine patients was significantly greater (p less than 0.05) than that observed in the endoscopically normal ranitidine group. "
10/01/1983 - "The results of a six week double blind placebo controlled trial (stage I) in 36 patients shows that ranitidine (150 mg bd) is superior to placebo in the acute treatment with significant symptomatic improvement concerning heartburn and regurgitation, and in healing or improvement of endoscopic lesions. "
04/01/1999 - "All three ranitidine doses were statistically significantly superior to placebo in providing overall episodic heartburn relief for the first episode (P < 0.002), last episode (P</=0.004), and all episodes combined (P < 0.001). "
04/01/1999 - "The ranitidine 75 mg regimen was clinically (> 10 percentage points) and statistically (P < 0.05) significantly more effective than placebo for all measured efficacy end-points in relieving heartburn and reducing antacid consumption. "
|3.||lansoprazole (Prevacid)FDA LinkGeneric
09/01/2009 - "Both lansoprazole 15 and 30 mg were highly effective and well tolerated in reducing symptoms in subjects with frequent nighttime heartburn. "
08/20/2010 - "In addition, the proportion of 24-hour heartburn-free days (primary endpoint) was significantly greater in recipients of dexlansoprazole MR 30 mg once daily than in recipients of placebo following 4 weeks' treatment in a large, randomized, double-blind, multicentre phase III trial in patients with NERD. "
07/01/2001 - "Failure patients had significantly poorer health outcomes during their lansoprazole trial periods with significantly greater severity of heartburn and severity and frequency of acid regurgitation (P < 0.001). "
11/01/2013 - "EE patients receiving dexlansoprazole 60 mg had significantly greater improvements in heartburn/regurgitation and heartburn-only subscales at week 4 compared with those receiving lansoprazole. "
11/01/2013 - "NERD patients receiving dexlansoprazole 30 and 60 mg experienced significantly greater improvements in symptom severity for both heartburn and regurgitation compared with placebo. "
|4.||rabeprazole (Aciphex)FDA Link
05/01/2010 - "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs. placebo: 82.58% and 62.17% (ITT; P < 0.0001) [per protocol 86.74% rabeprazole vs. 74.93% placebo (P < 0.0254)]. "
06/01/2002 - "After a 2-wk, single-blind placebo run-in phase, patients were randomized to receive 10 mg or 20 mg of rabeprazole or placebo once daily for 4 wk. Rabeprazole rapidly and effectively relieved heartburn, with significant improvements on day 1 of dosing. "
08/01/2000 - "Rabeprazole was also significantly more effective than placebo in preventing relapse of day-and night-time heartburn severity, maintaining overall patient well-being, and reducing antacid use. "
08/01/2000 - "There were also significant differences between the two groups favoring rabeprazole with respect to resolution or improvement of heartburn symptoms and improvement in sense of well-being. "
08/01/2011 - "Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid. "
06/01/2014 - "Antacids and H2 RAs are not recommended for treatment of frequent heartburn, while OTC PPIs are both indicated for, and effective for, treatment of frequent heartburn. "
12/01/2002 - "(i) both gums promptly decreased heartburn and elevated oesophageal pH; (ii) both gums provided sustained relief for 120 min; (iii) antacid gums provided faster and more prolonged symptom relief and pH control than chewable antacids. "
11/23/1998 - "Subjects with at least 3 months of frequent heartburn relieved by antacids, and with heartburn on at least 4 of 7 days during the week prior to study entry, had their medical history and gastrointestinal pathological characteristics recorded. "
07/01/2006 - "The case of a 56-year-old man with recurrent retrosternal heartburn no longer relieved by antacids is discussed. "
04/01/1999 - "Adult out-patients who reported heartburn relieved by antacids at least seven times per week were eligible. "
|6.||pantoprazole (Protonix)FDA LinkGeneric
11/01/2011 - "After 1.4 ± 0.0 months of treatment with pantoprazole, any sleep disturbance had improved in more than 75% of patients, with resolution of nighttime heartburn and regurgitation in, respectively, 75 and 83%. "
01/01/2005 - "Those patients relieved from heartburn entered the long-term phase, and were randomly assigned to either treatment group pantoprazole 20 mg, 40 mg or placebo. "
01/01/2003 - "Daytime and night-time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. "
01/01/2005 - "Patients with mild GORD grade 0 or 1 and heartburn of at least moderate intensity at the start of the study were treated with pantoprazole 20mg once daily for 28 days (n = 254). "
01/01/2009 - "Mild regurgitation and pyrosis persisted; therefore the patient continued to receive pantoprazole 40 mg for a further 3 weeks."
|7.||Proton Pump InhibitorsIBA
03/01/2006 - "To determine if H2-receptor antagonists used in conjunction with proton pump inhibitors were effective for nocturnal heartburn in patients taking proton pump inhibitors. "
07/01/2004 - "This could explain the reportedly low efficacy of proton pump inhibitors in functional heartburn and suggests considering different management strategies."
07/01/2004 - "Different pathophysiological characteristics could explain the reportedly low efficacy of proton pump inhibitors in functional heartburn. "
09/01/2003 - "Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs."
08/01/2011 - "One hundred fifty-six subjects with heartburn and/or regurgitation ≥3 days/week and either no history of taking proton pump inhibitors (PPIs naive, n=58) or at least partial symptom response to PPI therapy (PPI responsive, n=98) were enrolled in this randomized, double-blind, placebo-controlled trial. "
|8.||Cisapride (Propulsid)FDA Link
04/01/2000 - "and cisapride reduced the severity of daytime heartburn. "
06/01/1999 - "One hundred and twenty-two patients (45 men and 77 women, 22-65 years of age) who experienced heartburn during the 3 h after ingestion of the meal qualified for the double-blind phase of the study and were randomly assigned to either cisapride 20 mg or matching placebo b.d. "
10/01/2002 - "Cisapride did not significantly alter heartburn severity. "
04/01/2002 - "Cisapride increased lower oesophageal sphincter tone from 12.7 +/- 2.8 mmHg with placebo to 16.9 +/- 3.9 mmHg (P=0.03), and decreased heartburn episodes and antacid consumption. "
06/01/1999 - "Heartburn was prevented in a significantly higher percentage of cisapride-treated patients (40%; 24 out of 60) than placebo-treated patients (21%; 12 out of 58) after the repeat provocative meal at the end of the double-blind phase (P = 0.017). "
|9.||Cimetidine (Biomet)FDA LinkGeneric
07/01/1991 - "The improvement in heartburn symptoms was significantly greater in the combination group than in the group taking full dose cimetidine. "
10/01/1979 - "Cimetidine gave significantly greater relief of heartburn than antacid regardless of the initial randomization. "
01/01/1994 - "In patients with GI symptoms starting NSAID therapy and in patients on NSAID with a heartburn problem, cimetidine seems to be of value."
01/01/1994 - "Only 5.6% in the cimetidine group reported heartburn compared to 19.2% in the placebo group. "
04/01/1991 - "One hundred and twenty-five patients with symptoms of heartburn and acid regurgitation but without endoscopic abnormalities were randomized to receive 200 mg cimetidine suspension four times daily or placebo for two weeks. "
|10.||Nizatidine (Axid)FDA LinkGeneric
11/01/1994 - "Compared with placebo, nizatidine 150 mg twice daily was highly effective in rapidly reducing the severity of heartburn, regardless of oesophagitis severity at entry. "
11/01/1994 - "Twice-daily administration of nizatidine 150 mg or 300 mg provides prompt relief from the major symptom of GORD, heartburn, and complete healing of oesophagitis is seen in many patients."
07/28/1997 - "Single doses of 225 mg and 75 mg of nizatidine administered 30 minutes before a standard meal intended to provoke heartburn are significantly more effective than placebo for the prevention and/or reduction of postprandial heartburn."
11/01/1994 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after 1 day of therapy versus placebo. "
06/01/1992 - "The nizatidine 150 mg treatment group had significantly greater improvement in daytime and nighttime heartburn severity after one day of therapy versus placebo. "
08/01/2007 - "After laparoscopic Nissen fundoplication, frequency and severity scores dramatically improved for all symptoms queried (P < 0.001), especially for heartburn frequency (8, 8 +/- 3.2 versus 2, 3 +/- 2.8, P < 0.001) and severity (10, 8 +/- 2.9 versus 1, 2 +/- 2.5, P < 0.001). "
10/01/2005 - "In our hands, a Nissen fundoplication with complete mobilization of the fundus yielded the best results, a Nissen-Rossetti operation had more disphagia and more reoperations and a partial fundoplication of Toupet, had a higher incidence of recurrent heartburn."
12/01/2001 - "Although all symptoms were improved by fundoplication, resolution was more likely for heartburn than for atypical symptoms. "
01/01/2008 - "Nissen fundoplication in refractory patients, either open or laparoscopic, was effective in control of heartburn in 95% of patients contrary to 50% in mixed symptoms."
01/01/2015 - " proportion of people with heartburn at short term (surgery: 29/288 (adjusted proportion = 10.0%); medical: 59/266 (22.2%); RR 0.45, 95% CI 0.30 to 0.69; participants = 554; studies = 1), medium term (surgery: 12/288 (adjusted proportion = 4.2%); medical: 59/266 (22.2%); RR 0.19, 95% CI 0.10 to 0.34; participants = 554; studies = 1), long term (surgery: 46/111 (adjusted proportion = 41.2%); medical: 78/106 (73.6%); RR 0.56, 95% CI 0.44 to 0.72); participants = 217; studies = 1) and those with reflux symptoms at short-term (surgery: 6/288 (adjusted proportion = 2.0%); medical: 53/266 (19.9%); RR 0.10, 95% CI 0.05 to 0.24; participants = 554; studies = 1) and medium term (surgery: 6/288 (adjusted proportion = 2.1%); medical: 37/266 (13.9%); RR 0.15, 95% CI 0.06 to 0.35; participants = 554; studies = 1) was less in the laparoscopic fundoplication group than in the medical treatment group. "
03/01/2007 - "At 3 or 6 months after treatment, heartburn scores were significantly improved compared with pretreatment scores (5.0 +/- 1.7 pretreatment vs. 0.7 +/- 1.4 posttreatment, P=0.007). "
06/01/1982 - "After treatment both groups showed significant improvement in heartburn and in healing of esophageal lesions. "
05/28/2005 - "The median of the first time needed in relieving heartburn sensation was 1 d for both groups and the remission rates for heartburn on the 1st d after treatment were 77.3% and 65%, respectively (NS). "
06/01/2012 - "After treatment, heartburn and regurgitation disappeared in 93 and 87% of the patients, respectively. "
01/01/2010 - "Symptoms were evaluated before and after treatment with PPI on the period of three months and were recorded with heartburn system score and regurgitation score. "
01/01/2007 - "It is a safe and effective self-medication for on-demand treatment of heartburn."
09/01/1997 - "The commonest reasons for self-medication were heartburn (88%), gastrointestinal pain (31%), and acid regurgitation (32%). "
06/15/1995 - "The commonest response was self-medication (39.84%), especially when dealing with pain and Pyrosis. "
04/01/2012 - "The principal morbidities for seeking self-medication included cough and common cold as reported by 94 students (35.21%) followed by diarrhea (68 students) (25.47%), fever (42 students) (15.73%), headache (40 students) (14.98%) and pain abdomen due to heartburn/ peptic ulcer (23 students) (8.61%). "
04/01/1999 - "Although many rely on self-medication with antacids for the relief of their symptoms, treatments that decrease gastric volume as well as increase the pH of refluxed material should be more effective in relieving heartburn. "
05/01/2014 - "With respect to gastrectomy-associated symptoms, reflux and heartburn were more frequent in PG-EG patients, while dumpling syndrome was more frequent after TG-RY. "
01/01/2005 - "After distal gastrectomy, five patients had reflux symptoms of heartburn and regurgitation; 11 had none. "
07/01/1995 - "No significant differences were found between total gastrectomy with pouch reconstruction and distal gastric resection with respect to dumping or heartburn, whereas patients with total gastrectomy and restoration with esophagojejunostomy suffered from both. "
06/01/1993 - "Thirty gastrectomy patients with heartburn and regurgitation, and 8 healthy controls were studied. "
08/01/1990 - "No significant differences were found between total gastrectomy or distal gastric resection with respect to dumping or heartburn, while patients with proximal gastric resection suffered from both. "
|5.||Gastric Bypass (Roux-en-Y Gastric Bypass)
10/01/2003 - "Results of this study show that laparoscopic gastric bypass and laparoscopic Nissen fundoplication are both effective in treating heartburn symptoms and objective acid reflux in morbidly obese patients. "
10/01/2003 - "We hypothesized that, in morbidly obese patients, gastric bypass surgery would be as effective as Nissen fundoplication in reducing both heartburn symptoms and esophageal acid exposure, as reflected by the DeMeester score. "
10/01/2003 - "Comparison of objective outcomes following laparoscopic Nissen fundoplication versus laparoscopic gastric bypass in the morbidly obese with heartburn."
10/01/2003 - "The health benefits of weight loss after laparoscopic gastric bypass should make this operation the procedure of choice in the morbidly obese patient with heartburn."
10/01/2003 - "A life-saving surgical alternative for the morbidly obese patient is gastric bypass surgery, which usually improves heartburn symptoms in addition to many serious health conditions such as diabetes, hypertension, and sleep apnea. "